102 related articles for article (PubMed ID: 19075657)
21. Computer-guided design, synthesis, and biological evaluation of quinoxalinebisarylureas as FLT3 inhibitors.
Göring S; Bensinger D; Naumann EC; Schmidt B
ChemMedChem; 2015 Mar; 10(3):511-22. PubMed ID: 25677073
[TBL] [Abstract][Full Text] [Related]
22. Midostaurin for the treatment of adult patients with newly diagnosed acute myeloid leukemia that is FLT3 mutation-positive.
Garcia JS; Percival ME
Drugs Today (Barc); 2017 Oct; 53(10):531-543. PubMed ID: 29286055
[TBL] [Abstract][Full Text] [Related]
23. Targeting FMS-related tyrosine kinase receptor 3 with the human immunoglobulin G1 monoclonal antibody IMC-EB10.
Youssoufian H; Rowinsky EK; Tonra J; Li Y
Cancer; 2010 Feb; 116(4 Suppl):1013-7. PubMed ID: 20127944
[TBL] [Abstract][Full Text] [Related]
24. Discovery of 3-phenyl-1H-5-pyrazolylamine derivatives containing a urea pharmacophore as potent and efficacious inhibitors of FMS-like tyrosine kinase-3 (FLT3).
Lin WH; Hsu JT; Hsieh SY; Chen CT; Song JS; Yen SC; Hsu T; Lu CT; Chen CH; Chou LH; Yang YN; Chiu CH; Chen CP; Tseng YJ; Yen KJ; Yeh CF; Chao YS; Yeh TK; Jiaang WT
Bioorg Med Chem; 2013 Jun; 21(11):2856-67. PubMed ID: 23618709
[TBL] [Abstract][Full Text] [Related]
25. The role of FLT3 inhibitors in the treatment of FLT3-mutated acute myeloid leukemia.
Fathi AT; Chen YB
Eur J Haematol; 2017 Apr; 98(4):330-336. PubMed ID: 28000291
[TBL] [Abstract][Full Text] [Related]
26. Combining structure- and property-based optimization to identify selective FLT3-ITD inhibitors with good antitumor efficacy in AML cell inoculated mouse xenograft model.
Heng H; Wang Z; Li H; Huang Y; Lan Q; Guo X; Zhang L; Zhi Y; Cai J; Qin T; Xiang L; Wang S; Chen Y; Lu T; Lu S
Eur J Med Chem; 2019 Aug; 176():248-267. PubMed ID: 31103903
[TBL] [Abstract][Full Text] [Related]
27. Discovery of N
Gucký T; Řezníčková E; Radošová Muchová T; Jorda R; Klejová Z; Malínková V; Berka K; Bazgier V; Ajani H; Lepšík M; Divoký V; Kryštof V
J Med Chem; 2018 May; 61(9):3855-3869. PubMed ID: 29672049
[TBL] [Abstract][Full Text] [Related]
28. MZH29 is a novel potent inhibitor that overcomes drug resistance FLT3 mutations in acute myeloid leukemia.
Xu B; Zhao Y; Wang X; Gong P; Ge W
Leukemia; 2017 Apr; 31(4):913-921. PubMed ID: 27773927
[TBL] [Abstract][Full Text] [Related]
29. Aromatic interactions with phenylalanine 691 and cysteine 828: a concept for FMS-like tyrosine kinase-3 inhibition. Application to the discovery of a new class of potential antileukemia agents.
Furet P; Bold G; Meyer T; Roesel J; Guagnano V
J Med Chem; 2006 Jul; 49(15):4451-4. PubMed ID: 16854049
[TBL] [Abstract][Full Text] [Related]
30. Lyn is an important component of the signal transduction pathway specific to FLT3/ITD and can be a therapeutic target in the treatment of AML with FLT3/ITD.
Okamoto M; Hayakawa F; Miyata Y; Watamoto K; Emi N; Abe A; Kiyoi H; Towatari M; Naoe T
Leukemia; 2007 Mar; 21(3):403-10. PubMed ID: 17230226
[TBL] [Abstract][Full Text] [Related]
31. Bis(1H-2-indolyl)-1-methanones as inhibitors of the hematopoietic tyrosine kinase Flt3.
Teller S; Krämer D; Böhmer SA; Tse KF; Small D; Mahboobi S; Wallrapp C; Beckers T; Kratz-Albers K; Schwäble J; Serve H; Böhmer FD
Leukemia; 2002 Aug; 16(8):1528-34. PubMed ID: 12145694
[TBL] [Abstract][Full Text] [Related]
32. FLT3 tyrosine kinase as a target in acute leukemias.
Griffin JD
Hematol J; 2004; 5 Suppl 3():S188-90. PubMed ID: 15190306
[No Abstract] [Full Text] [Related]
33. The antitumor compound triazoloacridinone C-1305 inhibits FLT3 kinase activity and potentiates apoptosis in mutant FLT3-ITD leukemia cells.
Augustin E; Skwarska A; Weryszko A; Pelikant I; Sankowska E; Borowa-Mazgaj B
Acta Pharmacol Sin; 2015 Mar; 36(3):385-99. PubMed ID: 25640477
[TBL] [Abstract][Full Text] [Related]
34. Investigational drugs targeting FLT3 for leukemia.
Ustun C; DeRemer DL; Jillella AP; Bhalla KN
Expert Opin Investig Drugs; 2009 Oct; 18(10):1445-56. PubMed ID: 19671038
[TBL] [Abstract][Full Text] [Related]
35. FLT3 inhibition in acute myeloid leukaemia.
Knapper S
Br J Haematol; 2007 Sep; 138(6):687-99. PubMed ID: 17655729
[TBL] [Abstract][Full Text] [Related]
36. Identification of a potent 5-phenyl-thiazol-2-ylamine-based inhibitor of FLT3 with activity against drug resistance-conferring point mutations.
Chen CT; Hsu JT; Lin WH; Lu CT; Yen SC; Hsu T; Huang YL; Song JS; Chen CH; Chou LH; Yen KJ; Chen CP; Kuo PC; Huang CL; Liu HE; Chao YS; Yeh TK; Jiaang WT
Eur J Med Chem; 2015 Jul; 100():151-61. PubMed ID: 26081023
[TBL] [Abstract][Full Text] [Related]
37. FLT3 inhibitors in acute myeloid leukemia.
el-Shami K; Stone RM; Smith BD
Expert Rev Hematol; 2008 Dec; 1(2):153-60. PubMed ID: 21082920
[TBL] [Abstract][Full Text] [Related]
38. Discovery and Rational Design of Pteridin-7(8H)-one-Based Inhibitors Targeting FMS-like Tyrosine Kinase 3 (FLT3) and Its Mutants.
Sun D; Yang Y; Lyu J; Zhou W; Song W; Zhao Z; Chen Z; Xu Y; Li H
J Med Chem; 2016 Jul; 59(13):6187-200. PubMed ID: 27266526
[TBL] [Abstract][Full Text] [Related]
39. Effect of FLT3 inhibition on normal hematopoietic progenitor cells.
Weisel KC; Yildirim S; Schweikle E; Kanz L; Möhle R
Ann N Y Acad Sci; 2007 Jun; 1106():190-6. PubMed ID: 17442779
[TBL] [Abstract][Full Text] [Related]
40. Gö6976, a FLT3 kinase inhibitor, exerts potent cytotoxic activity against acute leukemia via inhibition of survivin and MCL-1.
Yoshida A; Ookura M; Zokumasu K; Ueda T
Biochem Pharmacol; 2014 Jul; 90(1):16-24. PubMed ID: 24735609
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
